EP2424507A4 - Zusammensetzungen und verfahren zur behandlung von insulinresistenz und diabetes mellitus - Google Patents

Zusammensetzungen und verfahren zur behandlung von insulinresistenz und diabetes mellitus

Info

Publication number
EP2424507A4
EP2424507A4 EP10770213A EP10770213A EP2424507A4 EP 2424507 A4 EP2424507 A4 EP 2424507A4 EP 10770213 A EP10770213 A EP 10770213A EP 10770213 A EP10770213 A EP 10770213A EP 2424507 A4 EP2424507 A4 EP 2424507A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
diabetes mellitus
insulin resistance
treating insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10770213A
Other languages
English (en)
French (fr)
Other versions
EP2424507A1 (de
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2424507A1 publication Critical patent/EP2424507A1/de
Publication of EP2424507A4 publication Critical patent/EP2424507A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP10770213A 2009-04-27 2010-04-27 Zusammensetzungen und verfahren zur behandlung von insulinresistenz und diabetes mellitus Withdrawn EP2424507A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17313409P 2009-04-27 2009-04-27
PCT/US2010/032620 WO2010126908A1 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Publications (2)

Publication Number Publication Date
EP2424507A1 EP2424507A1 (de) 2012-03-07
EP2424507A4 true EP2424507A4 (de) 2012-10-24

Family

ID=43032520

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10770213A Withdrawn EP2424507A4 (de) 2009-04-27 2010-04-27 Zusammensetzungen und verfahren zur behandlung von insulinresistenz und diabetes mellitus

Country Status (9)

Country Link
EP (1) EP2424507A4 (de)
JP (2) JP2012525396A (de)
CN (1) CN102413817B (de)
AU (1) AU2010241736B2 (de)
BR (1) BRPI1013992A2 (de)
CA (1) CA2758738A1 (de)
IL (1) IL215925A0 (de)
MX (1) MX2011011333A (de)
WO (1) WO2010126908A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007128721A1 (de) 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphe
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AU2011285545B2 (en) 2010-08-05 2014-03-13 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
HUE057267T2 (hu) 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
US9492404B2 (en) 2010-08-12 2016-11-15 Revalesio Corporation Compositions and methods for treatment of taupathy
ES2777890T3 (es) * 2010-11-15 2020-08-06 Boehringer Ingelheim Int Terapia antidiabética vasoprotectora y cardioprotectora
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
CA2831606A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
WO2013003620A2 (en) 2011-06-28 2013-01-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
ES2864203T3 (es) 2011-09-16 2021-10-13 Forsight Vision4 Inc Aparato de intercambio de fluido
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP6159584B2 (ja) * 2012-06-14 2017-07-05 松本　高明 輸液、輸液の製造方法および輸液装置
CH706747A2 (de) * 2012-07-17 2014-01-31 Hanspeter Steffen Verfahren zur Hydration, Straffung und Pflege der Haut, zur Behandlung von Dermatosen, Sonnenbrand und genereller Wunden mit Diamantelektroden hergestelltem Elektrolysewasser.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP4302736A3 (de) 2013-03-28 2024-04-03 ForSight Vision4, Inc. Ophthalmisches implantat zur abgabe von therapeutischen substanzen
JP2016063804A (ja) * 2013-12-27 2016-04-28 亀井 一郎 ミトコンドリア活性化組成物
US20170056438A1 (en) * 2014-10-17 2017-03-02 Aqua Zest Corporation Nanobubble-containing composition and use thereof
KR102416726B1 (ko) 2014-07-15 2022-07-05 포사이트 비젼4, 인크. 안구 이식물 전달 디바이스 및 방법
WO2016022750A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN114587774A (zh) 2014-11-10 2022-06-07 弗赛特影像4股份有限公司 治疗眼睛的系统
JP6674748B2 (ja) * 2015-05-27 2020-04-01 花王株式会社 Ｇｌｐ−１分泌促進剤
AU2016355345A1 (en) 2015-11-20 2018-05-31 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
AR108177A1 (es) 2016-04-05 2018-07-25 Forsight Vision4 Inc Dispositivos de suministro de fármacos oculares implantables
CN105878194A (zh) * 2016-06-07 2016-08-24 沈阳药科大学 一种格列本脲纳米结晶制剂及其制备方法
CN106362166B (zh) * 2016-10-27 2019-12-10 武汉大学 肿瘤坏死因子受体相关泛支架和信号蛋白在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
CA3082891A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
CN110006871A (zh) * 2019-02-20 2019-07-12 常州大学 一个基于外源性组胺检测的细胞模型以及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (de) * 1990-10-02 1992-04-16 Buchholz Klaus L Verwendung eines reaktionsproduktes aus einem gas und einer flüssigkeit, sowie verfahren und vorrichtung zu seiner herstellung
WO2002060458A2 (en) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
WO2006133113A2 (en) * 2005-06-03 2006-12-14 BAGLEY David System for making and conditioning super-oxygenated and structured water
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
WO2009055729A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for treating inflammation
WO2009055614A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
WO2008052145A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US20080154795A1 (en) * 2006-12-25 2008-06-26 Amos Alon Auction platform and applications
JP2008156320A (ja) * 2006-12-26 2008-07-10 Hydrox Kk 抗酸化性機能水

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (de) * 1990-10-02 1992-04-16 Buchholz Klaus L Verwendung eines reaktionsproduktes aus einem gas und einer flüssigkeit, sowie verfahren und vorrichtung zu seiner herstellung
WO2002060458A2 (en) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
WO2006133113A2 (en) * 2005-06-03 2006-12-14 BAGLEY David System for making and conditioning super-oxygenated and structured water
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
WO2009055729A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for treating inflammation
WO2009055614A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010126908A1 *

Also Published As

Publication number Publication date
CA2758738A1 (en) 2010-11-04
AU2010241736A1 (en) 2011-12-22
JP2015229678A (ja) 2015-12-21
BRPI1013992A2 (pt) 2016-08-16
EP2424507A1 (de) 2012-03-07
WO2010126908A1 (en) 2010-11-04
CN102413817B (zh) 2014-12-17
AU2010241736B2 (en) 2016-01-28
JP2012525396A (ja) 2012-10-22
CN102413817A (zh) 2012-04-11
IL215925A0 (en) 2011-12-29
MX2011011333A (es) 2011-11-18

Similar Documents

Publication Publication Date Title
EP2424507A4 (de) Zusammensetzungen und verfahren zur behandlung von insulinresistenz und diabetes mellitus
HK1224144A1 (zh) 用於體重管理和改善血糖控制的方法和組合物
IL205554A (en) An insulin resistance treatment containing melanocortin
ZA201200224B (en) Long acting insulin composition
PT2252312E (pt) Métodos de prevenção ou tratamento de resistência a insulina
EP2120959A4 (de) Verfahren und zusammensetzungen zur behandlung von insulinresistenz, diabetes und diabetesbedingter dyslipidämie
PL3181134T3 (pl) Bifidobakterie do leczenia cukrzycy i stanów pokrewnych
HK1161275A1 (en) Halogen-stabilized insulin
EP2414535A4 (de) Biomarker im zusammenhang mit insulinresistenz und verfahren zu ihrer verwendung
ZA201100056B (en) Syringe with disabling mechanism
HK1164112A1 (en) Treating hyperglycemia with glp-1 glp-1
ZA201005628B (en) Injection syringe
SI2376077T1 (sl) Sestavek in metoda za zdravljenje diabetesa
EP2067781A4 (de) Mittel zur verbesserung der insulinresistenz
EP2386624A4 (de) Komplexes mikrobielles präparat zur behandlung von diabetes sowie verfahren zu seiner herstellung und verwendung
EP2480246A4 (de) Zusammensetzung und verfahren zur behandlung von diabetes
HK1145452A1 (en) A pharmaceutical composition for treating diabetic nephropathy and the preparation method thereof
GB201009713D0 (en) A pharmaceutical composition for treating diabetes and preparation methods thereof
EP2797619A4 (de) Glypican-4 basierte zusammensetzungen und verfahren zur behandlung und diagnose von insulinresistenz
PT2557920E (pt) Composição que compreende uma membrana de casca de ovo em pó para utilização no tratamento de diabetes mellitus
PT2459207E (pt) Composição farmacêutica para tratamento de condições médicas e um método para tratamento de distúrbios alimentares e doenças relacionadas
HK1157690A1 (en) Syringe
GB0812019D0 (en) Insulin
EP2455090A4 (de) Mittel zur hemmung der erhöhung des postprandialen blutinsulinspiegels
HK1145453A1 (en) A pharmaceutical composition for treating diabetic nephropathy and the preparation method and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120926

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/02 20060101ALI20120920BHEP

Ipc: A61K 9/08 20060101ALI20120920BHEP

Ipc: A61K 31/58 20060101ALI20120920BHEP

Ipc: A61K 33/00 20060101ALI20120920BHEP

Ipc: A61K 9/00 20060101ALI20120920BHEP

Ipc: A61K 45/06 20060101ALI20120920BHEP

Ipc: A61K 9/14 20060101AFI20120920BHEP

17Q First examination report despatched

Effective date: 20151008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171103